Proactive Investors - Run By Investors For Investors

Pfizer reveals easing of fourth quarter revenue

“I was pleased with the company’s overall performance during 2016," said chief executive Ian Read.
Pfizer corporate headquarters in New York
Pfizer generated US$13.6bn of revenue in the fourth quarter

Dollar strength was one of the reasons given as Pfizer Inc (NYSE: PFE) revealed a reduction in the fourth quarter financials.

The drug Viagra and Lyrica maker generated US$13.6bn of revenue, down 3% compared to US$14bn in the same three months of 2015.

Over the full year revenues amounted to US$52.8bn which was an 11% increase from US$48.8bn.

“Pfizer-standalone revenues in 2016 grew 5% operationally, excluding the impact of foreign exchange as well as legacy Hospira and legacy Medivation operations, reflecting solid underlying growth despite significant headwinds from product losses of exclusivity and the decline in revenues for Prevnar 13 Adult in the US,” said chief financial officer Frank D’Amelio.

Meanwhile, chief executive Ian Read added: “I was pleased with the company’s overall performance during 2016 and believe both of our businesses executed well despite a challenging operating environment.

“We generated attractive operational revenue and earnings growth driven by our major products within both the Innovative Health and Essential Health businesses.”

View full PFE profile View Profile

Pfizer Timeline

Article
November 23 2015

Related Articles

scientist with vial
September 25 2018
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology
Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
1543827262_757z468_1542845960_Paradigm-cover.JPG
December 03 2018
The readout of clinical trials is expected this month.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use